A recent publication on a 111-patient trial on BioLight’s IOPtiMate CO2 laser surgical system suggests it provides intraocular pressure (IOP) reduction comparable to trabeculectomy, but potentially with a better safety profile. Sales in Europe and Asia are ongoing, and we expect clarity on a US regulatory strategy in H117. The firm had NIS31.8m in net cash at 30 September 2016 and we derive an rNPV valuation of NIS90.5-104.2m.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs